-

Lyndra Therapeutics to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that members of its management team will present and host one-on-one meetings at the 33rd Annual Piper Sandler Virtual Healthcare Conference taking place November 30 through December 2, 2021.

An on-demand, pre-recorded presentation will be made available on the conference website starting on Monday, November 22, 2021 at 10:00 a.m. ET.

About Lyndra Therapeutics

Lyndra Therapeutics is pioneering ultra-long-acting oral therapies, which has never been done before. The company’s novel delivery system will allow people to take medicines once a week, or even less often, instead of every day. Their breakthrough oral capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something that has the potential to fundamentally change the way people take medicine. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of poor or undesirable outcomes, including central nervous system diseases, oral contraception and opioid use disorder, among others. Lyndra’s lead product candidate, weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the company’s website at www.lyndra.com.

Contacts

Investor Contact
Christopher Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media Contact
Dan Boyle
Orangefiery
dan@orangefiery.com
(818) 209-1692

Lyndra Therapeutics


Release Summary
Lyndra Therapeutics today announced it will present at the 33rd Annual Piper Sandler Virtual Healthcare Conference Nov. 30 to Dec. 2, 2021.
Release Versions

Contacts

Investor Contact
Christopher Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media Contact
Dan Boyle
Orangefiery
dan@orangefiery.com
(818) 209-1692

More News From Lyndra Therapeutics

Lyndra Therapeutics Announces Adam Sayer Appointed President and CEO

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics®, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced the Board of Directors has appointed Adam Sayer as President and Chief Executive Officer effective immediately. He will also serve on the company’s Board of Directors. Sayer was most recently Chief Transformation Officer at Envision Healthcare, overseeing strategy, transformation and payer negotiations. His deep understanding of the healthcar...

Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, in which Thermo Fisher will provide global clinical research and commercial manufacturing services to Lyndra for its long-acting oral therapies. Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (...

Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study Demonstrating Efficacy of Oral Weekly Risperidone Compared to Daily Risperdal...
Back to Newsroom